Neurodegenerative Disease Research, Non-GMP Synthesis of Compounds
ID: 75N95024Q00460Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/6c4ed3eff47c4cee834fae0e7ea6b861/view
Timeline
    Description

    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking non-GMP synthesis of compounds for Neurodegenerative Disease Research. This service is typically used to identify molecules that bind KIAA0203 protein, with the potential to create a new Alzheimer's Drug. The vendor will perform the synthesis of up to 100 compounds in 2-10 milligram quantities under non-GMP conditions. The estimated period of performance is twelve months, with four additional twelve month option periods. Interested parties must demonstrate their capability to independently perform the synthesis and provide necessary information for the award decision. Responses must be submitted by July 28, 2024, 2:00 p.m. Eastern Time to Tracy Cain at tracy.cain@nih.gov.

    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Neurodegenerative Disease Research, Non-GMP Synthesis of Compounds
    Currently viewing
    Special Notice
    Similar Opportunities
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the preparation and distribution of research drug products under a presolicitation notice. The contract will involve acquiring, importing, and exporting drugs and chemical compounds, as well as developing and analyzing various drug dosage forms, including marijuana and nicotine research cigarettes, to support drug abuse and addiction research. This contract is critical for maintaining a reliable supply of authentic controlled and uncontrolled drug compounds for the research community, with an anticipated award of one indefinite delivery, indefinite quantity (IDIQ) contract over a five-year period. Interested parties must possess a current DEA registration and comply with FDA’s current Good Manufacturing Practices, with proposals due approximately 45 days after the release of the RFP, expected on or about September 20, 2024. For further inquiries, contact Scott Duernberger at scott.duernberger@nih.gov or 301-594-0670.
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Phase I clinical trials aimed at developing small molecule and biologics therapeutics, as outlined in RFP No. 75N95024R00086. The selected contractor will be responsible for comprehensive services including protocol development, trial management, and reporting to regulatory agencies, with a focus on safety, tolerability, and pharmacokinetics of the investigational therapeutics. This initiative is crucial for advancing therapeutic development in the field of neurology, ensuring compliance with FDA and ICH GCP standards throughout the trial process. Proposals are due by October 3, 2024, with a contract performance period from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. Interested parties can contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301 for further information.
    Brand-Name or Equal Axion Biosystems 48-well microelectrode array plates for the National Center for Advancing Translational Sciences
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of Axion Biosystems 48-well microelectrode array plates, essential for neurotoxicity screening assays in drug development. The acquisition includes 10 boxes of CytoView MEA 48 plates, which are crucial for evaluating the safety of antisense oligonucleotides in neurological treatments, facilitating the recording of neuronal electrical signals for toxicity assessments. Proposals are due by 4:00 PM EDT on September 9, 2024, with the anticipated award date set for September 12, 2024. Interested vendors should contact Mark McNally at mark.mcnally@nih.gov or 301-827-5869 for further details.
    A--PRECLINICAL MEDICATIONS SCREENING IN DEPENDENCE MO
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a contract focused on preclinical medications screening in models of Alcohol Use Disorder (AUD). The objective of this procurement is to conduct blind testing of compounds supplied by developers using mouse models, with the contractor responsible for generating analyses and reports throughout the project. This initiative is crucial for advancing research in alcohol use disorder treatments and ensuring compliance with NIH policies on reproducibility and animal welfare. Proposals are due by September 18, 2024, with the contract period commencing on December 1, 2024, and extending through November 30, 2031. Interested parties can contact Lisa Schaupp at lisa.schaupp@nih.gov or 301-827-8135 for further information.
    Evaluation of Semaglutide Safety and Tolerability in Adults with Cocaine Use Disorder with and without HIV and Assessment of Long-Acting Stimulants to Reduce Harm and HIV Transmission in Methamphetamine Use Disorder
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a non-competitive federal contract for the evaluation of semaglutide safety and tolerability in adults with cocaine use disorder, as well as the assessment of long-acting stimulants to reduce harm and HIV transmission in methamphetamine use disorder. The contract will focus on conducting two clinical research studies in the Baltimore/Washington, DC region, aligning with NIH's priorities to address HIV and related health issues. The anticipated contract will span three years, starting on September 30, 2024, with the University of Maryland Medical Center as the intended recipient. Interested parties may express their capabilities and interest by contacting Susan Nsangou at susan.nsangou@nih.gov, as this opportunity does not involve a competitive proposal process.
    Acquisition of Intravenous Stable Isotopes
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to acquire intravenous stable isotopes, namely 6,6 D2-glucose and D5 glycerol, for metabolic research purposes. This procurement is classified under NAICS code 325414 and is intended for a non-competitive contract with Pine Pharmaceuticals LLC, justified by the agency's determination that only this source can meet its specific needs. The isotopes are crucial for clinical studies, and the contract period is set from September 16, 2024, to September 15, 2025, with an estimated value below $250,000. Interested parties can reach out to Amber Harris at amber.harris@nih.gov for further inquiries regarding this opportunity.
    Genomics Sequencing Services for the NIAID Centralized Sequencing Program
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is seeking quotes for genomics sequencing services to support its Centralized Sequencing Program (CSP). The procurement aims to provide comprehensive whole genome sequencing, including variant interpretation and clinical reports, to enhance clinical research on infectious diseases, with results expected within four weeks of sample receipt. This initiative is critical for advancing the understanding of genetic factors in disease and improving patient care through genomic evaluations. Interested vendors must submit their quotes by 3:00 PM EST on September 13, 2024, to the primary contact, Seth Schaffer, at seth.schaffer@nih.gov, with the solicitation number RFQ-NIAID-24-2224314.
    Surveys and Cognitive Tasks
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), is seeking a vendor for a non-competitive contract to provide account management, planning, and maintenance for online crowd-sourced surveys and cognitive tasks related to depression and anxiety. The primary objective is to facilitate participation in these surveys for individuals both with and without mental health conditions, thereby supporting research efforts in this critical area. This procurement falls under NAICS code 541910, with a contract period of one year, and is scheduled for award on or around September 23, 2024. Interested parties must submit their capability statements and proposals by September 23, 2024, at 9:00 a.m. Eastern Standard Time, to Robin Knightly at Robin.Knightly@nih.gov.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Downstream Development Biolayer Interferometer Instrument: GatorPivot 16 Channel and Gator Pro 32 Channel Systems- Brand Name or Equal
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for the procurement of two Biolayer Interferometer Instruments, namely the GatorPivot 16 Channel and Gator Pro 32 Channel systems, to support monoclonal antibody and vaccine development projects. The instruments are critical for high-throughput quantification of proteins and protein epitopes, essential for vaccine efficacy and regulatory approval processes. Interested vendors must submit their quotes by September 13, 2024, with the expectation of delivery within 90 days post-award, and are encouraged to demonstrate their capability to meet the specified technical requirements. For inquiries, vendors can contact Hershea Vance at hershea.vance@nih.gov or Linda Smith at linda.smith2@nih.gov.